The Europe pharmaceutical CDMO market size was surpassed at USD 37.51 billion in 2025 and is predicted to reach around USD 73.79 billion by 2035, expanding at a CAGR of 7% from 2026 to 2035. The rising research and development activities, growing investments, and favorable government policies are boosting the market.

Europe Pharmaceutical CDMO Market Statical Scope

In Europe, the pharmaceutical CDMO market consists of companies that offer outsourced drug development and manufacturing services. European pharmaceutical companies are extensively outsourcing their development and manufacturing activities to CDMOs to reduce costs, access specialized expertise, and accelerate time -to -market.

The region's growth is largely attributed to its well -established healthcare infrastructure, availability of skilled personnel, increasing demand for injectable drugs, a rise in chronic diseases, higher investments in R&D for new drug development, and stringent regulatory requirements.

Europe Pharmaceutical CDMO Market Share, By Service Type, 2025 (%)

• API manufacturing - API manufacturing dominates the market, holding a share of 63.50%, driven by strong demand for high -quality active pharmaceutical ingredients, increasing outsourcing of bulk drug production, and growing emphasis on cost efficiency.
• Finished dosage formulation (FDF) development and manufacturing - Finished dosage formulation (FDF) development and manufacturing account for a share of 26.50%, supported by increasing demand for complex dosage forms and growing focus on end -to -end drug development services.
• Secondary packaging - Secondary packaging holds 10% of the market, driven by regulatory requirements for labeling, product safety, and increasing demand for efficient packaging and supply chain solutions.

Europe Pharmaceutical CDMO Market Share, By Research Phase, 2025 (%)

• Phase III - Phase III leads the market, holding a share of 32%, driven by increasing late -stage clinical development activities and growing demand for large -scale manufacturing and commercialization support.
• Phase IV - Phase IV accounts for a share of 26%, supported by rising focus on post -marketing surveillance, real -world evidence generation, and lifecycle management of approved drugs.
• Phase II - Phase II holds 22%, driven by growing emphasis on efficacy studies and expansion of mid -stage clinical pipelines.
• Phase I - Phase I represents 12%, supported by increasing early -stage clinical trials and demand for specialized small -batch manufacturing services.

Top Companies in the Europe Pharmaceutical CDMO Market

• Bushu Pharmaceuticals Ltd.
• Nipro Corporation
• Thermo Fisher Scientific Inc.
• Samsung Biologics
• Laboratory Corporation of America Holdings
• Siegfried Holding Ag
• Catalent, Inc
• Lonza Group AG
• Recipharm Ab
• Piramal Pharma Solutions
• Cordenpharma International
• Cambrex Corporation
• Wuxi Apptec

Segments Covered in the Report

By Service Type

• Active Pharmaceutical Ingredient (API) Manufacturing
  
  • Small Molecule
  • Large Molecule
  • High Potency (HPAPI)
• Finished Dosage Formulation (FDF) Development and Manufacturing
  
  • Solid Dose Formulation
  • Tablets
  • Others (Capsules, Powders, etc.)
  • Liquid Dose Formulation
  • Injectable Dose Formulation
• Secondary Packaging

By Research Phase

• Pre-clinical
• Phase I
• Phase II
• Phase III
• Phase IV